Fresenius Kabi Korea said Thursday that it has launched two high amino acid nutritional fluids, Ntense Injection and Ntense EF Injection.

Ntense, which means "Nitrogen intensify," a component of amino acids, is a three-chamber bag product that provides nutritional treatment for critically ill patients at high risk of muscle wasting even during short-term hospitalization and the protein-to-calorie ratio (1.5g:20kcal) required for critically ill patients.

While Ntense contains electrolytes in the active ingredient, Ntense EF does not contain electrolytes and is the only three-chamber bag product approved for Intradialytic Parenteral Nutrition (IDPN) during dialysis in Korea.

According to the International Guidelines for Critical Care Nutrition, high protein and moderate energy are recommended for critically ill adult patients requiring nutritional therapy. In addition, the Kidney Disease Outcome Quality Initiative (KDOQI) and European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines recommend IDPN as a treatment option to maintain or improve the nutritional status of hemodialysis patients.

"Ntense Injection provides a high protein and adequate calorie option for critically ill patients, while Ntense EF Injection can improve malnutrition in patients with electrolyte imbalances and hemodialysis patients," Fresenius Kabi Korea CEO Noah Park said.

Ntense Injection is available in four sizes -- 506 ml, 1012 ml, 1518 ml, and 2025 ml, while Ntense EF Injection is available in two sizes -- 506 ml and 1012 ml. They can be customized according to the patient's malnutrition status and calorie requirements.

On Thursday. 1, the insured drug price of Ntense and Ntense EF 1,012ml was announced at 40,197 won ($29.2) while Ntense and Ntense EF Ju 506ml and Ntense EF 1,518ml were announced at 26,798 and 50,246 won.